Trial Profile
A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Familial Mediterranean fever; Hereditary autoinflammatory diseases; Mevalonate Kinase Deficiency
- Focus Registrational; Therapeutic Use
- Acronyms CLUSTER
- Sponsors Novartis Pharmaceuticals
- 05 Sep 2023 Results assessing To assess efficacy, safety, and tolerability of canakinumab in patients with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) during a 72-week long-term, open-label extension of the CLUSTER study published in the Arthritis and Rheumatology
- 01 Nov 2022 Results (n=173) assessing the feasibility of the autoinflammatory disease activity index (AIDAI) as a tool to assess disease activity in patients with hereditary recurrent fever syndromes (HRFs) treated with canakinumab published in the Joint Bone Spine
- 23 Sep 2021 Results of an analysis assessing the long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency (MKD) of Epoch 4 during the open label extension published in the Rheumatology